Protalix Biotherapeutics (NYSEAMERICAN:PLX) posted its earnings results on Thursday. The company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.02, RTT News reports. The company had revenue of $14.25 million during the quarter, compared to analyst estimates of $11.60 million. During the same period in the previous year, the company earned ($0.10) EPS.
NYSEAMERICAN PLX traded down $0.01 during trading hours on Friday, reaching $0.22. The company had a trading volume of 224,000 shares, compared to its average volume of 554,562. Protalix Biotherapeutics has a 1-year low of $0.17 and a 1-year high of $0.60.
PLX has been the topic of a number of recent analyst reports. HC Wainwright set a $3.00 target price on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Friday, October 18th. Zacks Investment Research raised shares of Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th.
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
See Also: Stop Order
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.